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ABSTRACT
Purpose: To examine outcomes through
36 months in phakic eyes with newly
diagnosed primary open-angle glaucoma
(POAG) naı¨ve to therapy randomized to
treatment with two trabecular micro-bypass
stents or topical prostaglandin.
Methods: Subjects with POAG naı¨ve to therapy,
with intraocular pressure (IOP) C21 and
B40 mmHg, were randomized to implantation
of two stents or travoprost. Additional
medication was to be prescribed
post-treatment for elevated IOP or
glaucomatous optic nerve findings. Of 101
randomized subjects, 100 subjects were
followed for 24 months and 73 subjects were
followed for 36 months. Follow-up on all
subjects is ongoing.
Results: In this randomized cohort of 101
POAG subjects, 54 subjects underwent 2-stent
surgery and 47 received topical travoprost.
Mean pre-treatment IOP was 25.5 ± 2.5 mmHg
in stent-treated eyes and 25.1 ± 4.6 mmHg in
medication-treated eyes. By 3 years, mean IOP
was 14.6 mmHg in stent eyes (with medication
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added in 6 eyes) and 15.3 mmHg in travoprost
eyes (with a second medication added in 11
eyes). In the subset of eyes that did not require
additional medical therapy, mean IOP was
14.5 mmHg and 15.7 mmHg in the respective
groups. Ninety-one percent of stent eyes had
3-year IOP B18 mmHg without additional
therapy (62% B 15 mmHg) and 79% of
travoprost eyes had 3-year IOP B18 mmHg
(21% B 15 mmHg). Safety was favorable in
both groups.
Conclusions: In this prospective, randomized
comparison of subjects with newly diagnosed
POAG naı¨ve to therapy, substantial IOP
reduction with a favorable low complication
rate was shown through 3 years after either 2
trabecular stents implanted as the sole
procedure or topical travoprost therapy. These
data suggest 2-stent implantation may be a
viable initial treatment option comparable to
topical prostaglandin in newly diagnosed POAG
patients.
Trial registration: ClinicalTrials.gov identifier,
NCT01443988.
Funding: Glaukos Corporation, Laguna Hills,
CA.
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INTRODUCTION
Traditionally, treatment for newly diagnosed
open-angle glaucoma (OAG) has started with
topical ocular hypotensive medical therapy,
followed by laser trabeculoplasty. These
approaches have a lower risk profile than
filtering or drainage device surgery. Further,
these modalities preserve ocular tissues in
case more invasive surgery is eventually
required.
Despite these advantages, the efficacy of
medical and laser therapy is limited. Various
factors may hinder the proper use of topical
medications, such as side effects (e.g., ocular
hyperemia, iris hyperchromia, and periorbital
atrophy), cost, intolerance to topical
medications, and difficulty with drop
instillation [1, 2]. In addition, patient
adherence to medical therapy is frequently
documented to be low [3–6]. In one study of
28,741 patients are naı¨ve to glaucoma therapy,
for example, 70% of patients discontinued their
therapy after 1 year [3]. Such non-compliance
limits the actual vs. expected effect of medical
therapy and can increase the risk of disease
progression, cost to patients, and cost to
providers [7]. Laser procedures do not share
the same challenges as topical medications, but
their efficacy may be limited by short-term
inflammation and long-term attrition [8].
Surgical methods addressing outflow via
Schlemm’s canal have evolved over the last
15–20 years, from ab externo procedures such as
trabeculectomy and viscocanalostomy to
modern ab interno procedures such as
trabecular micro-bypass stent implantation
during micro-invasive glaucoma surgery
(MIGS) [9]. In particular, the iStent (iStent
Trabecular Micro-Bypass, Glaukos Corporation,
Laguna Hills, CA, USA) is a first-in-class
treatment for mild-moderate OAG and is
commercially available in the United States
and 28 other countries [10]. Implantation of a
single iStent in conjunction with cataract
surgery has been shown to safely lower
intraocular pressure (IOP) and medication
usage through up to 5 years postoperatively in
patients with glaucoma and cataract [11–17].
Implantation of multiple iStent devices during
cataract surgery or as a standalone procedure
also has shown effectiveness though up to
3 years postoperatively in patients with
162 Ophthalmol Ther (2016) 5:161–172
glaucoma not controlled on previous
medication regimens [18–21]. MIGS with
trabecular micro-bypass stents offers a highly
favorable safety profile compared to more
invasive traditional incisional glaucoma
surgery or more recent suprachoroidal stent
procedures [22–24].
To date, reports of trabecular micro-bypass
stent implantation have focused on patients
with mild to moderate OAG who have received
prior medical or surgical treatment for their
disease [11–22]. Due to its favorable safety and
clinical effectiveness, however, it is possible that
iStent implantation may be a suitable treatment
option for patients with newly diagnosed
glaucoma who are naı¨ve to therapy and who
require treatment long before they undergo
cataract surgery.
To address the potential utility of iStent as
initial therapy in these patients, we conducted a
prospective, randomized study to evaluate the
IOP-lowering effect and complication rates of
implanting two iStents as a standalone
procedure compared to primary medical
therapy in patients recently diagnosed with
OAG who had not undergone prior glaucoma
treatment. An earlier report showed IOP control
and favorable safety through 2 years [25]. The
present report covers outcomes through 3 years.
METHODS
This study was designed to enroll phakic
subjects with newly diagnosed primary OAG
(POAG), pseudoexfoliative glaucoma (PEX), or
ocular hypertension that had not undergone
prior treatment of any kind. Subjects were to
present at the screening exam with IOP C21 and
B40 mmHg, cup to disk (C:D) ratio B0.9, and
normal angle anatomy. The study excluded
subjects with uveitic, neovascular, or
angle-closure glaucoma; glaucoma associated
with vascular disorders; corneal pathology or
prior corneal surgery; congenital or traumatic
cataract or prior cataract surgery; retinal or optic
nerve disorders; or any ocular disease or
condition that, in the opinion of the
investigator, would place the subject at
significant risk, confound study results, or
interfere with study participation. Subjects
with fellow eyes in clinical trials and pregnant
or nursing women also were excluded.
The study site was the S.V. Malayan
Opthalmology Centre in Yerevan, Armenia.
Ethics committee approval was secured for
conduct of the study, and subjects signed
informed consent documents. The study was
conducted as per the principles governing
clinical research as set in the Declaration of
Helsinki 1964 (as revised in 2013) and
applicable ISO/GCP guidelines. The
ClinicalTrials.gov registration number for this
study is NCT01443988 [26].
One-hundred qualified subjects were to be
randomized in a 1:1 ratio under an open-label,
unmasked strategy for implantation with either
two iStent devices or topical travoprost (Travatan
0.004%; Alcon, Fort Worth, TX, USA). Stents
were implanted by one staff surgeon and a teamof
visiting surgeons (Appendix 1). Following
treatment, subjects were scheduled to return for
evaluations at day 1,week 1, and atmonths 1, 3, 6,
12, 18, 24, 30, 36, 42, 48, 54 and 60. Pre-treatment
and post-treatment examination at each
scheduled visit included measurement of IOP via
Goldmannapplanationtonometry,best-corrected
visual acuity (BCVA) via decimal chart, visual field
via Humphrey 24-2 Swedish Interactive
Thresholding Algorithm (SITA) standard
perimetry, corneal thickness via pachymetry,
slit-lamp evaluation, fundus examination and
clinical assessment of nerve abnormalities, C:D
ratio estimation, medication status, and
assessment of complications and surgical
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interventions. In the event of elevated IOP (e.g.,
[21 mmHg) or optic nerve findings’ (e.g.,
worsened nerve appearance together with visual
field progression) post-treatment, subjects were to
be treated with additional therapy. This included
initiating medical therapy in the stent group and
administering additional medication(s) in the
travoprost group.
The iStent device and implantation
technique have been described in detail in
previous work [12]. In brief, this single-piece,
titanium, heparin-coated device has an
L-shaped structure with a snorkel (inlet) on
the short side which resides in the anterior
chamber. The inlet opens to the half-pipe body
which resides in Schlemm’s canal. The stent is
1.0 mm long and 0.33 mm in height. The inlet
is 0.25 mm long with a bore diameter of
0.12 mm. The implant is provided to the
surgeon pre-loaded in a disposable, single-use,
stainless steel inserter that allows precise stent
insertion ab internally into Schlemm’s canal.
Once implanted, the stent is designed to create
a bypass through the trabecular meshwork to
Schlemm’s canal to improve aqueous outflow
through the physiologic natural pathway with
resultant decrease in IOP.
Travoprost topical ophthalmic solution is a
synthetic prostaglandin F analog. The drug
works to increase uveoscleral outflow and
provide subsequent IOP reduction. In this
study, brand-name Travatan (Alcon, Fort
Worth, TX, USA) was used. Patients were
instructed to instill medication once daily in
the evening at 8 pm.
We assessed mean IOP over time in all eyes
regardless of additional medical therapy after
the initial treatment, and mean IOP in eyes
that had not received additional therapy after
their initial stent or travoprost treatment.
Additional efficacy analysis included the
proportion of eyes that had postoperative
IOP B18 and B15 mmHg without additional
medical therapy. Analyses of safety consisted
of assessment of adverse events and
complications, visual field, C:D ratio, central
corneal thickness, and BCVA through the
36-month post-treatment period.
The randomized cohort population
consisted of subjects randomized to treatment
with two stents or travoprost (n = 101).
Analyses were performed on available eyes
from the Randomized Cohort preoperatively,
month 12, month 24 and month 36. Mean and





A total of 101 subjects (101 POAG, 1 PEX)
completed the screening examination and were
randomized to treatment with either two stents
or with travoprost. To eliminate different
diagnoses as a potential confounder, the one
subject with PEX was excluded from the current
analysis. Of the 101 subjects with POAG, 100
subjects completed follow-up through month
24 and 73 subjects completed follow-up
through month 36.
Demographics and pre-treatment parameters
are shown in Table 1. The stent and travoprost
groups were similar in age (64.5 ± 11.1 vs.
62.0 ± 11.3 years, respectively), screening IOP
(25.5 ± 2.5 vs. 25.1 ± 4.6 mmHg), C:D ratio
(0.7 ± 0.2 vs. 0.6 ± 0.1), visual field, central
corneal thickness, and BCVA. There were fewer
males in the 2-stent group (25/54 or 46%) than
in the medication group (32/47 or 68%). All
subjects were Caucasian.
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Efficacy
Subjects experienced notable reduction of IOP
following implantation of two iStent trabecular
micro-bypass devices or administration of
topical travoprost (Fig. 1). For the stent group,
mean IOP reduced from 25.5 mmHg
preoperatively to 14.6 mmHg at 3 years. For
the travoprost group, mean IOP reduced from
25.1 mmHg preoperatively to 15.3 mmHg at
3 years. By month 12, medication had been
added to 8 subjects (3 in stent group, 5 in
travoprost group) (Table 2). An additional 4 eyes
(2 per group) had medication added at or before
month 24. By the month 36 exam, an
additional 5 eyes (1 in stent group and 4 in
travoprost group) had medication added to
their original treatment. In the subset of eyes
that did not require additional medical therapy,
mean IOP at 3 years was 14.5 mmHg in the
stent group and 15.7 mmHg in the travoprost
group (Fig. 2).
Proportional analyses showed that 94%,
90%, and 91% of stent-treated eyes had IOP
B18 mmHg without the need for postoperative
medication at 1, 2 and 3 years, respectively,
while 89%, 87% and 79% of eyes in the
travoprost group achieved IOP B18 mmHg at
these timepoints without requiring additional
medical therapy. The majority (62%) of stent
eyes maintained IOP B15 mmHg through
3 years, while a decreasing percentage (21%) of
travoprost eyes maintained IOP B15 mmHg
over the 3-year follow-up period (Fig. 3).
Safety
Safety was favorable in both groups. Two
complications were reported during stent
insertion in the surgery group, both of which
were attributed to subject movement during
surgery: one of these subjects had hyphema
which resolved by day 1 and one subject had a
small iridodialysis which resulted in no
postoperative ocular sequelae. No other
operative complications were reported.
In general, BCVA was stable over time for
both groups (Fig. 4). Progression of cataract over
the 3-year follow-up period was reported in 11
eyes (20%) in the stent group and 8 eyes (17%)
in the travoprost group. Of these, cataract
surgery was performed in 6 eyes (5 in stent
group and 1 in travoprost group), with last
reported BCVA of 20/40 or better in these
operated eyes. In the remaining non-operated
subjects, three-year BCVA was 20/40 or better in
6 eyes (2 in stent group and 4 in med group),













Mean (SD) 0.7 (0.2) 0.6 (0.1)
Corneal thickness (lm)
Mean (SD) 552.6 (41.2) 540.3 (59.2)
Preop medicated IOP (mmHg)
Mean (SD) 25.5 (2.5) 25.1 (4.6)
BCVA (snellen)
20/40 or better 40 (74%) 39 (83%)
20/100 or better 52 (96%) 47 (100%)
20/200 or better 54 (100%) 47 (100%)
BCVA best-corrected visual acuity, C:D cup to disk, IOP
intraocular pressure, OD/OS right eye/left eye, SD
standard deviation
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20/100 in 1 eye (stent group), and 20/200 in 6
eyes (3 per group). No other post-treatment
adverse events were reported in either group.
As shown in Table 3, C:D ratio, visual field,
and central corneal thickness were
stable through 36 months in both groups
compared to pre-treatment values.
DISCUSSION
The goal of this prospective, randomized study
was to compare the IOP reduction and safety
profile of two ab interno trabecular micro-bypass
stents (iStent) vs. topical prostaglandin
medication in eyes with newly diagnosed
POAG. Both therapies demonstrated
substantial IOP reduction through 3 years
post-treatment. Without starting additional
medications, IOP B15 mmHg was maintained
in the majority of stent eyes through 3 years of
follow-up, but in only a minority of medication
eyes. In addition, a lower percentage of stent
eyes (11.1%; 6/54) compared to travoprost eyes
(23.4%; 11/47) required additional medication
by 3 years. Both groups had similarly favorable
safety profiles, including stable BCVA, C:D
ratio, visual fields, and central corneal
thickness. These data support consideration of
multiple iStent implantations as a first-line
treatment option comparable to topical
prostaglandin for newly diagnosed POAG
patients who face decisions about the
management of their chronic disease.
Prior studies of trabecular micro-bypass stent
implantation have focused on patients with
mild to moderate OAG who have received
previous medical or surgical treatment [11–18].
There is a relative paucity of glaucoma studies
in newly diagnosed glaucoma patients who are
naı¨ve to treatment. Thus, the present study
showing clinical outcomes of 2-iStent
implantation in treatment-naı¨ve eyes fills a
key gap in the literature. These findings may
be increasingly relevant as more surgeons are
Fig. 1 Mean IOP (mmHg) and number of subjects through 3 years, available eyes of randomized cohort*. IOP intraocular
pressure
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considering iStent implantation as initial
treatment for their newly diagnosed glaucoma
patients.
iStent implantation as initial therapy may
offer several benefits over topical medications,
whose utility may be limited by issues such as
side effects and patient compliance
[1–7, 27–30]. Furthermore, the cost of both
brand-name and generic medications places a
considerable financial burden on the newly
diagnosed glaucoma patient [31], thus making
a longstanding surgical solution even more
appealing. This may be particularly important
in glaucoma patients, the majority of whom
have at least one additional chronic condition
requiring medication [32].
In this study, the IOP decrease in the
travoprost group was greater than the 25–35%
IOP reductions reported in prior work [33–35].
This may be due to medication-naı¨ve eyes, high
compliance due to study participation, and/or
regression to the mean. The greater IOP
Table 2 Subjects with post-treatment medical therapy, randomized cohort




IOP (mmHg) at exam
when med was added
Medication added
2-Stent group (N = 54)
37 30 Month 1 30 Brimonidine, timolol
61 25 Month 1 26 Taﬂuprost
72 26 Month 3 23 Travoprost, timolol
7 24 Month 18 16b Taﬂuprost
82 25 Month 18 18b Timolol
34 28 Month 36 19b Timolol
Travoprost group (N = 47)
56 38 Month 1 26 Brinzolamide, timolol
62 32 Month 1 28 Brinzolamide
93 29 Month 1 23 Brinzolamide
81 38 Month 3 32 Brinzolamide
97 30 Month 3 25 Brinzolamide, timolol
41 21 Month 24 20b Timolol
76 26 Month 24 18b Timolol
4 23 Month 30 19b Betoptic
65 29 Month 30 18b Betoptic
10 22 Month 36 19b Timolol
14 22 Month 36 19b Timolol
IOP intraocular pressure
a Does not reﬂect all study visits following treatment. The complete schedule of postoperative visits for both groups was as
follows: day 1, week 1, and at months 1, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
b Medication added due to optic nerve ﬁndings
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reduction also may be attributed to the
pre-treatment IOP level (i.e., greater IOP
reduction with higher preoperative IOP), a
phenomenon which has been reported
previously in both treated and treatment-naı¨ve
glaucoma patients [35, 36].
There are several limitations to this study.
Given the surgical vs. medical therapy study
design, neither subjects nor clinicians were
masked to treatment. Diurnal measurements
of IOP were not performed. A pre-treatment
grading of the crystalline lens was not used,
and guidelines for when to perform cataract
surgery were not standardized. Future work
could incorporate such measures to address
these study limitations, and also could
encompass postoperative follow-up past
3 years. In addition, future analyses may
examine the long-term cost effectiveness of
Fig. 2 Mean IOP (mmHG) and number of subjects through 3 years in Eyes without additional medical therapy, available
eyes of randomized cohort*. IOP intraocular pressure
Fig. 3 Proportional analysis of post-treatment IOP,
percent B15, B18 mmHg without additional therapy,
available eyes of randomized cohort*. IOP intraocular
pressure
Fig. 4 Proportional analysis of BCVA through 3 years,
available eyes of randomized cohort*. BCVA best-corrected
visual acuity, PRE preoperative
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iStent implantation vs. topical medication
administration.
CONCLUSIONS
In summary, data from this prospective,
randomized, controlled study provide a direct
comparison of two trabecular micro-bypass
stents vs. prostaglandin medical therapy in
newly diagnosed POAG. In both groups,
patients showed substantial IOP reduction and
favorable safety through 3 years. These findings
support the viability of multiple iStent
implantations as an initial treatment option
comparable to topical prostaglandin in newly
diagnosed POAG.
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